All In MedTech

Device Trial Radar · NCT05898711

Kerecis Case Registry for SurgiBind : Soft Tissue Reinforcement

Quality and Safety Outcomes: Prospective Follow Up Registry on FDA Cleared Acellular Fish Skin Grafts in Soft Tissue Reinforcement.

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

Mar 25, 2022

Primary completion

Oct 29, 2024

Study completion Jan 3, 2025

Sponsor

Lead sponsor
Kerecis Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Jun 12, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Registry Objectives The overall objective of the registry is to collect quality and safety data to assess the long-term outcomes of Kerecis Omega3 SurgiBind in surgical procedures to reinforce soft tissue and prevent surgical complications. The ultimate goal of the registry is to enhance the quality of care, patient outcomes and establish a resource to facilitate the use of fish skin in preventing surgical wound dehiscence and surgical site infection.

Conditions

  • Surgery-Complications

Interventions

  • Fish skin graftDevice

    Kerecis Fish Skin Graft - SurgiBind

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of surgical complication: dehiscence, infectionTime frame: 12 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Northern Illinois Foot and Ankle Specialists

    Crystal Lake, Illinois

  • Mount Sinai

    New York, New York

  • Cone Health OrthoCare Greensboro

    Greensboro, North Carolina

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.